Innovative Therapies and Clinical Studies for Screenable Disorders (R21)

Program Announcement (PA) Number: PAR-06-059
This PAR will use the NIH exploratory/developmental research grant (R21) award mechanism.


Executive Summary
  • The National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for research relevant to the basic understanding and development of therapeutic interventions for currently screened conditions and “high priority” genetic conditions for which screening could be possible in the near future.  In this PAR, a “high priority” condition is a condition for which the development of an efficacious therapy would make the condition amenable to newborn screening.
  • Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.
  • This PAR will use the NIH exploratory/developmental research grant (R21) award mechanism. 
  • Eligible organizations include: for-profit and non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government; and domestic or foreign institution/organizations. 
  • Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research.  Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
  • Applicants may submit more than one application, provided they are scientifically distinct.

Last Edited: 12/22/05 04:35 PM by Evette Mezger